Information Provided By:
Fly News Breaks for December 19, 2019
Dec 19, 2019 | 06:40 EDT
BofA/Merrill analyst Brian Cheng initiated coverage of Apellis Pharmaceuticals with a Buy rating and $36 price target. The analyst expects the company's paroxysmal nocturnal hemoglobinuria in January for APL-2 should validate C3 as a therapeutic target in diseases mediated by complement. He believes the value of the totality of data is being overlooked by investors.
News For APLS From the Last 2 Days
There are no results for your query APLS